Sodium-myo-inositol cotransporter 1 (SMIT1) (SMIT1)

Sodium-myo-inositol cotransporter 1 (SMIT1), encoded by the SLC5A3 gene, is a high-affinity, sodium-dependent symporter responsible for the uptake of myo-inositol into various cell types, particularly within the brain and kidneys [1, 5]. It plays a dual role in cellular physiology by acting as a key regulator of intracellular osmolarity and providing the essential substrate for the phosphoinositide signaling cycle [1]. In the context of neuropsychiatric treatment, SMIT1 is a primary target of the 'inositol depletion hypothesis,' which suggests that the therapeutic efficacy of mood stabilizers like carbamazepine stems from their ability to lower intracellular inositol levels [2, 3]. While carbamazepine is also well-known as a sodium channel blocker, it has been shown to directly inhibit SMIT1-mediated transport, thereby dampening the overactive signaling pathways associated with manic episodes and epileptic seizures [4]. Beyond its neurological importance, SMIT1 is vital for the survival of cells under hypertonic stress, as seen in the renal medulla and during diabetic complications [5]. Consequently, the modulation of this transporter represents a significant mechanism for controlling both neuronal excitability and osmotic homeostasis.

Other names

SLC5A3Sodium/myo-inositol cotransporterSolute carrier family 5 member 3SMITInositol transporter

Carbamazepine acts as a non-competitive inhibitor of the Sodium-myo-inositol cotransporter 1 (SMIT1), which reduces the uptake of myo-inositol from the extracellular environment into the cytoplasm [2, 4]. This inhibition leads to a decrease in intracellular myo-inositol concentrations, effectively limiting the availability of inositol for the resynthesis of phosphoinositides like phosphatidylinositol 4,5-bisphosphate (PIP2) [3]. By depleting these signaling precursors, the drug attenuates overactive G-protein coupled receptor signaling pathways that rely on the inositol triphosphate (IP3) and diacylglycerol (DAG) second messengers, which is hypothesized to stabilize mood in bipolar disorder and reduce neuronal hyperexcitability in epilepsy [2, 4].